GABA

Recent articles

Research image of excitatory synapses in the prefrontal cortex.

Synaptic anomalies in autistic people support imbalance hypothesis

Increased excitatory and decreased inhibitory synapses in the prefrontal cortex of autistic people suggest broader impacts on brain function and connectivity.

By Giorgia Guglielmi
27 June 2024 | 4 min read
Image of the dorsal raphe area of the brain.

Neurotransmitter switch-up helps fan extreme stress into full-blown fear

The flip occurs when certain neurons in the dorsal raphe start to express the chemical GABA instead of glutamate, a new study shows.

By Claudia López Lloreda
9 April 2024 | 5 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Looking at eye tracking’s potential for clinical trials

This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.

By Calli McMurray
28 September 2023 | 6 min read
Photograph of white pills and blister pack on blue pastel colored background.

Trials of arbaclofen for autism yield mixed results

Autistic children taking the drug showed improvements in some behaviors but not in their social skills.

By Giorgia Guglielmi
5 May 2023 | 5 min read
Research image of cultured neurons.

Cannabis compound rebalances signaling to quell seizures in mice

Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.

By Peter Hess
22 March 2023 | 5 min listen

Single gene insufficient to account for dup15q, Angelman traits

UBE3A, a key gene associated with both autism-linked conditions, can explain most — but not all — of the syndromes’ atypical neuronal properties.

By Angie Voyles Askham
21 March 2023 | 6 min read
Illustration of hybrid objects: part light bulb, part lab vial, some in blue and some in red to signify null and replicated results.

Null and Noteworthy: Busting biomarkers; going after GABA; reproducibility illusion

In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.

By Laura Dattaro
16 February 2023 | 4 min read
A hand reaches from above to add a pill to a stack that is resting against the x-axis of a graph.

Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses

Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.

By Peter Hess
25 January 2023 | 6 min read
Single astrocyte on black background.

Mouse studies cast astrocytes as stars of sensory perception

Data from two separate research teams suggest the cells are key to sensory hypersensitivity in fragile X syndrome.

By Sarah DeWeerdt
13 November 2022 | 4 min read
Laura Cancedda in Iama's lab.

Building a better drug

Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.

By Alla Katsnelson
6 October 2022 | 12 min read

Explore more from The Transmitter

Illustration of a brain with a window opening into it.

To understand the brain as a network organ, we must image cortical layers

Human neuroscience research has largely overlooked this spatial scale—which bridges cells and brain areas. But new advances in functional MRI technology are changing that.

By Laurentius Huber
2 June 2025 | 6 min read
Research image of EEG scans showing dopamine levels in human brains.

Null and Noteworthy: Learning theory validated 20 years later

The first published paper from the EEGManyLabs replication project nullifies a null result that had complicated a famous reinforcement learning theory.

By Laura Dattaro
30 May 2025 | 4 min read
Gerry Fischbach.

Neuroscientist Gerry Fischbach, in his own words

In 2023, I had the privilege of sitting down with Gerry over the course of several days and listening as he told the story of his life and career—including stints as dean or director of such leading institutions as Columbia University and NINDS—so that we could record it for posterity.

By Ivan Oransky
30 May 2025 | 2 min read